Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MabSpace's Second-Gen PD-L1 Candidate Approved for US Trial

publication date: Feb 22, 2018

Suzhou's MabSpace Biosciences reports its lead candidate, MSB2311, a second-gen PD-L1 candidate, has been approved to start US clinical trials. The company plans a first-in-human study of MSB2311 in patients with locally advanced or metastatic solid tumors. MabSpace filed for China IND approval of the molecule in October 2017. With its proprietary drug discovery program, MabSpace has formed several partnerships with other China-connected novel drug developers, though it continues to hold worldwide rights to MSB2311. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital